Quick Dispatch:
Your step 6 semaglutide Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5 - Kushner - 2020 - Obesity orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your step 6 semaglutide Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5 - Kushner - 2020 - Obesity ships.
Need Help?
Questions about step 6 semaglutide Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5 - Kushner - 2020 - Obesity, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for step 6 semaglutide Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5 - Kushner - 2020 - Obesity in your area.
00008-0/asset/044847a7-65f8-406f-af79-a6041876c4a7/main.assets/gr2_lrg.jpg)
Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial -
23.59
00008-0/asset/3402d8bd-b094-4f9e-a1fd-f6e857029ffa/main.assets/gr1.gif)
Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial -
26.95
Summary of primary and secondary efficacy endpoints for STEP 1-6 and
28.45
00388-1/asset/ea6ce183-9bef-430d-8294-d1c4f42feac0/main.assets/gr2_lrg.jpg)
Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial
23.21
Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial -
25.81
Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype
26.24
Effect of once‐weekly subcutaneous semaglutide 2.4 mg on weight‐ and health‐related quality of life in an East Asian population: Patient‐reported outcomes from the STEP 6 trial - Kolotkin - 2023
29.01
